SML3020
Taltirelin acetate
≥98% (HPLC)
Synonym(s):
(4S)-Hexahydro-1-methyl-2,6-dioxo-4-pyrimidinecarbonyl-L-histidyl-L-prolinamide, (S)-N-((S)-1-((S)-2-Carbamoylpyrrolidin-1-yl)-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl)-1-methyl-2,6-dioxohexahydropyrimidine-4-carboxamide, (S)-N-[(Hexahydro-1-methyl-2,6-dioxo-4-pyrimidinyl)carbonyl]-L-histidyl-L-prolinamide, TA 0910, TA-0910, TA0910
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C17H23N7O5 · xC2H4O2
Molecular Weight:
405.41 (free base basis)
NACRES:
NA.77
UNSPSC Code:
12352107
Biochem/physiol Actions
Thyrotropin-releasing hormone (TRH) mimetic with greatly enhanced brain-penetration, oral activity, stability and in vivo efficacy than TRH.
Taltirelin (TA-0910) is a thyrotropin-releasing hormone (TRH) mimetic with greatly enhanced brain-penetration, oral activity and stability. Taltirelin shortens the duration of pentobarbital-induced sleep (0.3-3 mg/kg po. or 0.03-0.3 mg/kg iv.), antagonizes reserpine-induced hypothermia (1 or 3 mg/kg po. or 0.1-0.3 mg/kg ip.), and enhances the spontaneous motor activity (30 mg/kg po.) in mice in vivo, while TRH produces these effects at about 100 times higher doses.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
涉药品监管产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
M Yamamura et al.
Japanese journal of pharmacology, 53(4), 451-461 (1990-08-01)
Effects of orally administered TA-0910, a new thyrotropin-releasing hormone (TRH) analog, on the central nervous system (CNS) were investigated and compared with those of TRH. TA-0910 shortened the duration of pentobarbital-induced sleep and antagonized reserpine-induced hypothermia at 0.3 mg/kg or
John P Dougherty et al.
Behavioural brain research, 360, 255-261 (2018-12-12)
Fatigue is a common symptom in many diseases and disorders and can reduce quality of life, yet lacks an adequate pharmacological intervention. To identify and develop such interventions, and to better understand fatigue, additional preclinical research is necessary. However, despite
Cong Zheng et al.
Frontiers in cellular neuroscience, 12, 485-485 (2019-01-09)
Dopaminergic neurons loss is one of the main pathological characters of Parkinson's disease (PD), while no suitable neuroprotective agents have been in clinical use. Thyrotropin-releasing hormone (TRH) and its analogs protect neurons from ischemia and various cytotoxins, but whether the
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service